Predecir el riesgo de enfermedad también tiene riesgos | 16 FEB 20

Promesas y peligros de las pruebas genéticas

Para la toma de decisiones clínicas, se debe considerar la validez, la precisión predictiva, la utilidad clínica, los posibles daños, la rentabilidad y la viabilidad de su uso en la atención de rutina.
Autor/a: Ian A Scott, John Attia, Ray Moynihan Fuente: BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m14 Promises and perils of using genetic tests to predict risk of disease
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas
  1. Regalado A. 2017 was the year consumer DNA testing blew up. MIT Technology Review. 12 Feb 2018. https://www.technologyreview.com/s/610233/2017-was-the-year-consumer-dna-testing-blew-up/
  2. Hogarth S, Saukko P. A market in the making: the past, present and future of direct-to-consumer genomics. New Genet Soc2017;36:197-208doi:10.1080/14636778.2017.1354692 .
  3. Buniello A, MacArthur JAL, Cerezo M, et al The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res2019;47(D1):D1005-12. doi:10.1093/nar/gky1120 pmid:30445434
  4. Wilson BJ, Nicholls SG. The Human Genome Project, and recent advances in personalized genomics. Risk Manag Healthc Policy2015;8:9-20. doi:10.2147/RMHP.S58728 pmid:25733939
  5. Diamandis EP, Li M. The side effects of translational omics: overtesting, overdiagnosis, overtreatment. Clin Chem Lab Med2016;54:389-96. doi:10.1515/cclm-2015-0762 pmid:26444364
  6. Lek M, Karczewski KJ, Minikel EV, et al., Exome Aggregation Consortium. Analysis of protein-coding genetic variation in 60,706 humans. Nature2016;536:285-91. doi:10.1038/nature19057 pmid:27535533
  7. Hersh CP, Demeo DL, Lange C, et al. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol2005;33:71-8. doi:10.1165/rcmb.2005-0073OC pmid:15817713
  8. McPherson R, Tybjaerg-Hansen A. Genetics of coronary artery disease. Circ Res2016;118:564-78. doi:10.1161/CIRCRESAHA.115.306566 pmid:26892958
  9. Shigemizu D, Abe T, Morizono T, et al. The construction of risk prediction models using GWAS data and its application to a type 2 diabetes prospective cohort. PLoS One2014;9:e92549. doi:10.1371/journal.pone.0092549 pmid:24651836
  10. Payton NM, Kalpouzos G, Rizzuto D, et al. Combining cognitive, genetic, and structural neuroimaging markers to Identify individuals with increased dementia risk. J Alzheimers Dis2018;64:533-42. doi:10.3233/JAD-180199 pmid:29889068
  11. Lee A, Mavaddat N, Wilcox AN, et al. BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med2019;21:1708-18. doi:10.1038/s41436-018-0406-9 pmid:30643217
  12. Kalf RR, Mihaescu R, Kundu S, de Knijff P, Green RC, Janssens AC. Variations in predicted risks in personal genome testing for common complex diseases. Genet Med2014;16:85-91. doi:10.1038/gim.2013.80 pmid:23807614
  13. Lourida I, Hannon E, Littlejohns TJ, et al. Association of lifestyle and genetic risk with incidence of dementia. JAMA2019;322:430-7. doi:10.1001/jama.2019.9879 pmid:31302669
  14. Stocker H, Möllers T, Perna L, Brenner H. The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores. Transl Psychiatry2018;8:166. doi:10.1038/s41398-018-0221-8 pmid:30143603
  15. Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet2018;50:1219-24. doi:10.1038/s41588-018-0183-z pmid:30104762
  16. So HC, Sham PC. Exploring the predictive power of polygenic scores derived from genome-wide association studies: a study of 10 complex traits. Bioinformatics2017;33:886-92, 17. doi:10.1093/bioinformatics/btw745 pmid:28065900
  17. Holliday EG, Scott RJ, Attia J. Evidence-based medicine in the era of biomarkers: teaching a new dog old tricks?Clin Pharmacol Ther2010;88:740-2. doi:10.1038/clpt.2010.214 pmid:21081940
  18. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science2003;302:643-6. doi:10.1126/science.1088759 pmid:14576434
  19. Moyer VA, U.S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: US Preventive Services Task Force recommendation statement. Ann Intern Med2014;160:271-81. doi:10.7326/M13-2747 pmid:24366376
  20. Lee AJ, Cunningham AP, Tischkowitz M, et al. Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet Med2016;18:1190-8. doi:10.1038/gim.2016.31 pmid:27464310
  21. Lill CM. Genetics of Parkinson’s disease. Mol Cell Probes2016;30:386-96. doi:10.1016/j.mcp.2016.11.001 pmid:27818248
  22. Baglin T, Gray E, Greaves M, et al., British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol2010;149:209-20. doi:10.1111/j.1365-2141.2009.08022.x pmid:20128794
  23. Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol2015;33:3660-7. doi:10.1200/JCO.2015.63.0996 pmid:26324357
  24. Giardiello FM, Allen JI, Axilbund JE, et al., US Multi-Society Task Force on Colorectal Cancer. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology2014;147:502-26. doi:10.1053/j.gastro.2014.04.001 pmid:25043945
  25. Bao W, Hu FB, Rong S, et al. Predicting risk of type 2 diabetes mellitus with genetic risk models on the basis of established genome-wide association markers: a systematic review. Am J Epidemiol2013;178:1197-207. doi:10.1093/aje/kwt123 pmid:24008910
  26. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol2013;33:2261-6. doi:10.1161/ATVBAHA.112.301120 pmid:23599444
  27. Mega JL, Stitziel NO, Smith JG, et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet2015;385:2264-71. doi:10.1016/S0140-6736(14)61730-X pmid:25748612
  28. Umans-Eckenhausen MA, Defesche JC, van Dam MJ, Kastelein JJ. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med2003;163:65-8. doi:10.1001/archinte.163.1.65 pmid:12523918
  29. Mavaddat N, Michailidou K, Dennis J, et al., ABCTB Investigators, kConFab/AOCS Investigators, NBCS Collaborators. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am J Hum Genet2019;104:21-34. doi:10.1016/j.ajhg.2018.11.002 pmid:30554720
  30. Seibert TM, Fan CC, Wang Y, et al., PRACTICAL Consortium. Polygenic hazard score to guide screening for aggressive prostate canc
 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024